Amgen Inc

AMGN

Equity

ISIN null / Valor 907582

NASDAQ (2025-11-18)

USD 342.66+1.48%

Amgen Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

s a leading biotechnology company that focuses on addressing high unmet medical needs by developing innovative medicines to improve health outcomes and enhance the lives of patients worldwide. With a strong emphasis on science and innovation, Amgen leverages its expertise in understanding the biological mechanisms of disease to drive its discovery research efforts and build a deep pipeline of potential new medicines with breakthrough potential. Through its subsidiary deCODE Genetics, Amgen utilizes human genetics to identify and validate disease targets, further enhancing its research capabilities. As a global leader in biologics manufacturing, Amgen ensures the safe and reliable production of biologic medicines that are crucial for the treatment of millions of seriously ill patients. With a commitment to quality control and a reliable supply of medicines, Amgen's mission is to transform new ideas and discoveries into life-changing therapies for patients with serious illnesses.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Total revenues increased by 9% to $9.2 billion in the second quarter of 2025 compared to the same period in 2024. Product sales grew by 9%, driven by a 13% increase in volume, partially offset by a 3% decline in net selling prices.

Earnings Per Share Surge

GAAP earnings per share (EPS) surged by 92%, rising from $1.38 to $2.65, primarily due to higher revenues. Non-GAAP EPS also saw a robust increase of 21%, reaching $6.02 in the second quarter of 2025.

Operating Income and Margin Improvement

GAAP operating income rose from $1.9 billion to $2.7 billion, with the operating margin increasing by 6.6 percentage points to 30.3%. Non-GAAP operating income grew to $4.3 billion, and the non-GAAP operating margin expanded to 48.9%.

Strong Product Performance

Fifteen products achieved double-digit sales growth in the second quarter, including Repatha®, EVENITY®, and IMDYLLTRA™. Notably, UPLIZNA® sales increased by 91%, and BLINCYTO® grew by 45% year-over-year, highlighting the success of Amgen's diverse product portfolio.

Free Cash Flow Generation

The company generated $1.9 billion in free cash flow during the second quarter of 2025, slightly down from $2.2 billion in the same quarter of 2024. This decrease was driven by deferred tax payments and higher capital expenditures, partially offset by business performance.

Summarized from source with an LLMView Source

Key figures

20.5%1Y

18.9%3Y

47.0%5Y

Performance

27.7%1Y

24.6%3Y

23.1%5Y

Volatility